No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
QGEN240621P35000
- 0.15
- 0.000.00%
15min DelayTrading May 3 10:59 ET
0.00High0.00Low
0.00Open0.15Pre Close0 Volume222 Open Interest35.00Strike Price0.00Turnover190.95%IV16.74%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type-0.0632Delta0.0238Gamma279.07Leverage Ratio-0.1439Theta-0.0001Rho-17.63Eff Leverage0.0034Vega
Intraday
- 5D
- Daily
News
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Thursday.Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) fell sharply in today's pre-market trading
J.P. Morgan Maintains Qiagen NV(QGEN.US) With Buy Rating, Raises Target Price to $54
J.P. Morgan analyst Casey Woodring maintains $Qiagen NV(QGEN.US)$ with a buy rating, and adjusts the target price from $52 to $54.According to TipRanks data, the analyst has a success rate of 40.5% an
Express News | Qiagen NV : UBS Raises Target Price to $46 From $44
Qiagen Is Maintained at Overweight by JP Morgan
Qiagen Is Maintained at Overweight by JP Morgan
Express News | JP Morgan Maintains Overweight on Qiagen, Raises Price Target to $54
Qiagen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 22.13% JP Morgan $52 → $54 Maintains Overweight 05/01/2024 1.78% Stifel $55 → $45 Maintains Hol
Comments
Qiagen's high P/E ratio is worrisome due to its poor earnings forecast. Despite the high P/E, investors retain their shares, but this earnings growth rate may eventually impact the share price. The high P/E and future earnings predictions pose a substantial risk to shareholders and potential investors.
There's Reason For Concern Over Qiagen N.V.'s (NYSE:QGEN) PriceQiagen's performance is strong due to strategic profit reinvestment, leading to significant earnings growth. Its respectable ROE contributes to a net income increase. Yet, forecasts anticipate a slowdown in future earnings growth.
2
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $SolarEdge Technologies(SEDG.US$ - up 7.31%
2. $Kohl's Corp(KSS.US$ - up 4.46%
3. $DuPont(DD.US$ - up 4.38%
4. $Welltower Inc(WELL.US$ - up 4.02%
5. $CNH Industrial(CNHI.US$ - up 3.18%
6. $Planet Fitness(PLNT.US$ - up 3.46%
7. $Qiagen NV(QGEN.US$ - up 2.35%
8. $Taiwan Semiconductor(TSM.US$ - up 2.05...
Gap Ups
1. $SolarEdge Technologies(SEDG.US$ - up 7.31%
2. $Kohl's Corp(KSS.US$ - up 4.46%
3. $DuPont(DD.US$ - up 4.38%
4. $Welltower Inc(WELL.US$ - up 4.02%
5. $CNH Industrial(CNHI.US$ - up 3.18%
6. $Planet Fitness(PLNT.US$ - up 3.46%
7. $Qiagen NV(QGEN.US$ - up 2.35%
8. $Taiwan Semiconductor(TSM.US$ - up 2.05...
+17
18
Gapping up
$Qiagen NV(QGEN.US$ +3.4% (the biotech company raised its full-year outlook, pointing to particular strength in its non-Covid product portfolio.)
$Lordstown Motors(RIDE.US$ +14.6% (contract manufacturer Foxconn will invest up to $170 million in the electric vehicle maker and become its largest shareholder.)
$DuPont(DD.US$ +3.7% (the industrial materials maker beat top and bottom line estimates for the third quarter. Du...
$Qiagen NV(QGEN.US$ +3.4% (the biotech company raised its full-year outlook, pointing to particular strength in its non-Covid product portfolio.)
$Lordstown Motors(RIDE.US$ +14.6% (contract manufacturer Foxconn will invest up to $170 million in the electric vehicle maker and become its largest shareholder.)
$DuPont(DD.US$ +3.7% (the industrial materials maker beat top and bottom line estimates for the third quarter. Du...
9
1
Read more